FDA to review Merck's treatment for ragweed pollen allergy

05/10/2013 | Fox Business

The FDA has accepted Merck & Co.'s biologics-license application for a dissolvable immunotherapy tablet for ragweed pollen allergy. Merck expects the FDA to release its decision in the first half of next year. The sublingual tablet was developed in collaboration with ALK-Abello.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations